Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031092PMC
http://dx.doi.org/10.1016/j.htct.2019.01.008DOI Listing

Publication Analysis

Top Keywords

intravenous ferric
4
ferric carboxymaltose
4
carboxymaltose treatment
4
treatment iron
4
iron deficiency
4
deficiency anemia
4
anemia letter
4
letter editor
4
intravenous
1
carboxymaltose
1

Similar Publications

Introduction: Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder characterized by an uncontrollable urge to move the legs, typically accompanied by discomfort. Low iron levels, pregnancy, and age are some identified risk factors. RLS is treated using various pharmacological options, including dopamine agonists, benzodiazepines, anticonvulsants, opioids, and bupropion.

View Article and Find Full Text PDF

Ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease (IBD), often cause anemia, primarily due to iron deficiency and chronic inflammation. Anemia negatively affects patients' daily functioning and quality of life, causing symptoms including headaches, exhaustion, and dyspnea. In IBD, iron deficiency arises from reduced intake, chronic blood loss, and impaired absorption.

View Article and Find Full Text PDF

Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity.

Am J Hematol

January 2025

Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, USA.

View Article and Find Full Text PDF

Introduction: This retrospective, observational cohort study investigated the association between treatment of iron deficiency with conception results and pregnancy outcomes in women with infertility and iron deficiency, before and after intravenous ferric carboxymaltose infusion.

Material And Methods: Data were collected from electronic health records from the Dextra Fertility Clinic (Helsinki, Finland) between 2015 and 2020. The cohort included 292 women (<43 years) with infertility and iron deficiency (s-ferritin ≤30 μg/L), treated with a ferric carboxymaltose infusion (Ferinject®, 500 mg i.

View Article and Find Full Text PDF

Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!